Kanabo Group Plc
("Kanabo" or the "Company")
Investor Updates
Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis Company focussing on the development and distribution of cannabis-derived products for medical patients and wellness CBD consumers, has posted their latest investor newsletter and investor presentation to their website.
The latest Company presentation can be viewed here;
https://www.kanabogroup.com/wp-content/uploads/2022/03/Kanabo_GP_V01_230222.pdf
The Company has also posted a recent webinar with Vox Markets where Kanabo CEO, Avihu Tamir and GP Service CEO, Atul Devani discuss the GP Services acquisition. The webinar can be viewed here;
Watch the Kanabo webinar hosted by Vox Markets - Vox Markets
The latest Kanabo Investor Newsletter discussing the significant progress made over recent months can be viewed here; https://www.kanabogroup.com/press/foreword-from-the-ceo-march-11-2002/
For further information, please visit http://www.kanabogroup.com/ or contact the following:
| Kanabo Group Plc |
|
| Avihu Tamir, CEO | Via Vox Markets |
| Peterhouse Capital Ltd |
|
| Eran Zucker (Financial Adviser) | Tel: +44 (0)20 7469 0930 |
| Lucy Williams / Charles Goodfellow (Corporate Broker) | Tel: +44 (0)20 7469 0930 |
| Vox Markets (Investor Relations) |
|
| Kat Perez | KanaboGroup@voxmarkets.co.uk |
About Kanabo Group Plc
Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
